COMPLICATIONS HEMATOLOGIQUES
1. Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., Miller, C. B., Rarick, M. U., Regan, D. H., Browman, G. P., and Gordon, M. S. Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin.Oncol. 1-10-2002;20(19):4083-107
Recommandations 2002 de l'ASCO sur l'utilisation de l'érythropoïétine en cancérologie.
2. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100(12):2664-2670
Série de 9 cas.
3. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101(9):1936-1946.
Revue narrative sur la maladie du greffon contre l'hôte.
4. Pene F, Vigneau C, Auburtin M, Moreau D, Zahar JR, Coste J et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit.
Intensive Care Med 2005; 31(1):71-78.
Série rétrospective multicentrique de 63 patients (dont 14 avec cancer).
5. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 Jul 1;24(19):3187-205.
Recommandations 2006 de l'ASCO (mise à jour) sur l'utilisation des facteurs de croissance leucocytaires en cancérologie.
6. Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N et al. Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 2006; 34(8):2127-2133.
Etude de cohorte suggérant un effet bénéfique des échanges plasmatiques dans les microangiopathies thrombotiques.
7. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006 Nov 15;66(22):10643-6.
Revue narrative.
8. Zojer N, Ludwig H. Hematological emergencies. Ann Oncol 2007 Feb;18 Suppl 1:i45-i48.
Revue narrative.
9. Bosly A, Muylle L, Noens L, Pietersz R, Heims D, Hubner R, et al. Guidelines for the transfusion of platelets. Acta Clin Belg 2007 Jan;62(1):36-47.
Recommandations de pratique clinique.
10. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362: 600-13, 2010.
Etude prospective randomisée.
11. Souza-Dantas VC, Salluh JI, Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case-control study. Ann Oncol 2011 Sep;22(9):2094-100.
Etude cas-témoins.
12. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011 Sep 15;17(18):5858-66.
Revue narrative.
13. Agarwal S, O'Donoghue S, Gowardman J, Kennedy G, Bandeshe H, Boots R. Intensive care unit experience of haemopoietic stem cell transplant patients. Intern Med J 2012 Jul;42(7):748-54.
Etude rétrospective.
14. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012 Jul;91(4):195-205.
Etude rétrospective.
15. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013 May 9;368(19):1771-80.
Etude randomisée.